A trial to compare the safety of once weekly dosing of NNC0195-0092 with daily Norditropin® FlexPro® in previously human growth hormone treated adults with growth hormone deficiency

Mise à jour : Il y a 4 ans
Référence : U1111-1152-3664

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the clinical safety of once weekly dosing of NNC0195-0092 during 26 weeks of treatment in AGHD subjects previously treated with daily hGH


Critère d'inclusion

  • Growth hormone deficiency in adults